Effects of arecoline on phase I and phase II drug metabolizing system enzymes, sulfhydryl content and lipid peroxidation in mouse liver.
The modifying potential of arecoline alkaloid was studied on hepatic drug metabolizing system enzymes, acid soluble sulfhydryl (-SH) content and microsomal lipid peroxidation. Arecoline was administered intraperitoneally to Swiss albino mice at the dose levels of 10, 20 or 40 mg/kg body wt./day for 10 or 30 days. Significant increase in the levels of glutathione S-transferase (GST), cytochrome b5 (Cyt.b5), cytochrome P-450 (Cyt.P-450) and malondialdehyde (MDA) was observed in the arecoline treated groups. Decreased -SH content was apparent by the administration of 40 mg arecoline for 10 or 30 days. The modulation in biotransformation system enzymes has wide significance in the process of neoplastic development as well as in detecting the further role of biometabolized chemicals.
Singh
A
A
Cancer Biology Laboratory, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
Rao
A R
AR
D000818:Animals; D001115:Arecoline / Q000008:administration & dosage / Q000494:pharmacology*; D001711:Biotransformation; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D015786:Cytochromes b5 / Q000378:metabolism; D005260:Female; D005609:Free Radicals; D005982:Glutathione Transferase / Q000378:metabolism; D007274:Injections, Intraperitoneal; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D051379:Mice; D008862:Microsomes, Liver / Q000187:drug effects* / Q000378:metabolism; D013438:Sulfhydryl Compounds / Q000378:metabolism*
D005609:Free Radicals; D013438:Sulfhydryl Compounds; D001115:Arecoline; D008315:Malondialdehyde; D015786:Cytochromes b5; D003577:Cytochrome P-450 Enzyme System; D005982:Glutathione Transferase